Results 181 to 190 of about 61,152 (267)

Optimization of Hot and Cold‐Water Extractions of Cistus salviifolius L. for Enhanced Phenolic Content and Antimicrobial Efficacy

ChemistrySelect, Volume 11, Issue 13, 6 April 2026.
This study optimized cold and hot water extractions for maximizing phenolic content and antibacterial activity against S. aureus and P. aeruginosa. Hot water yielded higher total phenolics and were more effective against P. aeruginosa. Conversely, cold water enriched specific ellagitannins (punicalagin and cistusin), showing potent, targeted ...
Atalanti Christou, Alexandra Charilaou, Danae Markou, Nikolaos A. Parisis, Panayiota Piri, Konstantina Stavrou, Andreas G. Tzakos, George Botsaris, Ioannis P. Gerothanassis, Vlasios Goulas   +9 more
wiley   +1 more source

(D-Ala²)GIP Inhibits TNF-α-Induced Osteoclast Formation and Bone Resorption, and Orthodontic Tooth Movement. [PDF]

Int J Mol Sci
Lin A, Kitaura H, Ma J, Ohori F, Marahleh A, Kanou K, Narita K, Fan Z, Murakami K, Kanetaka H.   +9 more
europepmc   +1 more source

Dysfunctional Lipid‐Induced Secretion of Glucagon‐Like Peptide‐2(GLP‐2), but Not of Incretins Glucagon‐Like Peptide‐1(GLP‐1)/Glucose‐Dependent Insulinotropic Polypeptide(GIP), Promotes Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia

MedComm, Volume 7, Issue 4, April 2026.
Giovanni Musso, Silvia Pinach, Alberto Mella, Franco De Michieli, Anna Calabrese, Deborah Trifiro, Giovanna Petrangolini, Maurizio Cassader, Filippo Mariano, Roberto Gambino   +9 more
wiley   +1 more source

Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2651-2660, April 2026.
Abstract Aim Eloralintide (LY3841136) is a potent, long‐acting selective amylin receptor agonist currently under development for the treatment of obesity with once‐weekly subcutaneous dosing. Materials and Methods This 12‐week Phase 1, randomised, placebo‐controlled, participant‐ and investigator‐blinded, multiple ascending dose study evaluated the ...
Shobha Bhattachar, Lai San Tham, Beth Tidemann‐Miller, Hilda Ibriga, Hongchang Qu, Daniel A. Briere, Axel Haupt, Kieren J. Mather, Edward Pratt   +8 more
wiley   +1 more source

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2661-2671, April 2026.
Abstract Aims This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide.
Xi Tan, Yuanjie Liang, Lin Xie, Joanna Harton, Cynthia Gutierrez, Chalak Muhammad, Caroline Swift, Adam de Havenon   +7 more
wiley   +1 more source

Calcium-Sensing Receptor Regulation of Gastrointestinal Hormone Secretion.

Endocr Rev
Anjom-Shoae J, Veedfald S, Conigrave AD, Horowitz M, Feinle-Bisset C.   +4 more
europepmc   +1 more source

Investigating the role of melanocortinergic, glutamatergic and neuropeptide Y systems on hypophagia caused by gastric inhibitory polypeptide (GIP) in broilers. [PDF]

Poult Sci
Gharaie ML, Zendehdel M, Zarei H, Mahdavi K.   +3 more
europepmc   +1 more source

Dual action of imeglimin on insulin secretion and sensitivity in type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2744-2756, April 2026.
Abstract Aims Imeglimin is a novel oral hypoglycemic agent approved for the treatment of type 2 diabetes in Japan, with dual actions to enhance insulin secretion and improve insulin sensitivity, suggested by preclinical evidence. However, the effect of imeglimin on tissue‐specific insulin sensitivity and glucose kinetics using glucose tracers is ...
Tsubasa Tajima, Hideyoshi Kaga, Naoaki Ito, Toshiki Kogai, Hitoshi Naito, Saori Kakehi, Satoshi Kadowaki, Yuya Nishida, Ryuzo Kawamori, Yoshifumi Tamura, Hirotaka Watada   +10 more
wiley   +1 more source

Epicardial Adipose Tissue as a Cardiometabolic Target in Atrial Fibrillation: Implications for Ablation Strategies and Emerging Metabolic Therapies. [PDF]

Med Sci (Basel)
Cacciapuoti F.
europepmc   +1 more source

Effectiveness and adherence in a tirzepatide‐supported digital weight‐loss programme in Australia: A real‐world observational study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2835-2848, April 2026.
Abstract Aims Obesity is a growing global health crisis; pharmacotherapies such as tirzepatide combined with multidisciplinary lifestyle support have shown promise but real‐world evidence in digital weight‐loss services (DWLSs) is limited. This retrospective study evaluated 6‐ and 12‐month weight loss, adherence and predictors of outcomes in an ...
Louis Talay, Jason Hom, Tamara Scott, Neera Ahuja   +3 more
wiley   +1 more source